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Objectives The aim of this study was to compare single- versus dual-chamber implantable cardioverter-defibrillator (ICD)
implantation and complication rates in a large, real-world population.
Background The majority of patients enrolled in ICD efficacy trials received single-chamber devices. Although dual-chamber
ICDs offer theoretical advantages over single-chamber defibrillators, the clinical superiority of dual-chamber
models has not been conclusively proven, and they may increase complications.
Methods The National Cardiovascular Data Registry ICD Registry was used to examine the association between baseline char-
acteristics and device selection in 104,049 patients receiving single- and dual-chamber ICDs between January 1, 2006, and
December 31, 2007. A longitudinal cohort design was then used to determine in-hospital complication rates.
Results Dual-chamber devices were implanted in 64,489 patients (62%). Adverse events were more frequent with dual-
chamber than with single-chamber device implantation (3.17% vs. 2.11%, p  0.001), as was the rate of in-
hospital mortality (0.40% vs. 0.23%, p  0.001). After adjusting for demographics, medical comorbidities, diag-
nostic test data, and ICD indication, the odds of any complication (odds ratio: 1.40; 95% confidence interval:
1.28 to 1.52; p  0.001) and in-hospital mortality (odds ratio: 1.45; 95% confidence interval: 1.20 to 1.74;
p  0.001) were increased with dual-chamber versus single-chamber ICD implantation.
Conclusions In this large, multicenter cohort of patients, dual-chamber ICD use was common. Dual-chamber device implanta-
tion was associated with increases in periprocedural complications and in-hospital mortality compared with
single-chamber defibrillator selection. (J Am Coll Cardiol 2011;58:1007–13) © 2011 by the American College
of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.039Although the majority of patients enrolled in implantable
cardioverter-defibrillator (ICD) efficacy trials received single-
chamber devices (1–3), subsequent reports have revealed high
dual-chamber defibrillator implantation rates in real-world
populations (4). The addition of an atrial lead provides theo-
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2011, accepted April 27, 2011.retical advantages, although the clinical superiority of dual-
chamber models has not been conclusively proven (5–9). Atrial
lead placement has the potential to increase procedural com-
plications, and a higher rate of adverse events was described in
Canadian patients receiving dual- versus single-chamber defi-
brillators (10). To inform future device selection strategies, we
examined the prevalence and procedural complication rates of
single- versus dual-chamber ICD implantation in a cohort of
patients enrolled in the National Cardiovascular Data Registry
(NCDR) ICD Registry.
See page 1014
Methods
We studied the cross-sectional association between baseline
characteristics and device selection in patients who received
single- and dual-chamber devices in the NCDR ICD Registry.
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were then compared between de-
vice cohorts. Patient, device, and
procedural information was ob-
tained through a standardized form
submitted to the NCDR by the
implanting institution. Our anal-
ysis included all patients who
underwent first-time ICD im-
plantation between January 1,
2006, and December 31, 2007.
Patients receiving biventricular devices were excluded. A
procedural complication was defined as any adverse event
occurring between the time of ICD implantation and
hospital discharge.
Indications for cardiac pacing were based on class I and IIa
recommendations from the 2008 American College of Cardi-
ology, American Heart Association, and Heart Rhythm Soci-
ety Guidelines for Device-Based Therapy of Cardiac Rhythm
Abnormalities (11). Patients with the following indications
were considered to be appropriate candidates for dual-chamber
devices: second- or third-degree heart block, bradycardic car-
diac arrest, abnormal sinus node function, and previous pace-
maker implantation.
The NCDR Analysis Center at Yale University maintained
the primary data and performed all statistical analyses. Differ-
ences in baseline characteristics were compared between the
single- and dual-chamber ICD groups using F tests in
analysis-of-variance models for continuous variables. Propor-
tions were compared using chi-square or Fisher exact tests for
categorical variables. Procedural complication rates were com-
pared between cohorts using chi-square or Fisher exact tests.
Multivariate hierarchical logistic regression models adjusting
for potential confounders were used to determine whether
dual-chamber ICD therapy was associated with increased risk
for procedural complications compared with single-chamber
ICD implantation. Random-effect terms for implanting center
were included to address potential effects of clustering of
patients among hospitals.
Results
The NCDR ICD Registry recorded 104,049 first-time
implantations of single- or dual-chamber ICDs during the
study period (Fig. 1). Dual-chamber devices were implanted
in 64,489 patients (62%). Baseline characteristics are de-
scribed in Table 1. The proportion of patients who received
ual-chamber devices with an indication for cardiac pacing
s reported in Table 2. Abnormal sinus node function was
elatively common, while comparatively few patients had a
ocumented history of second- or third-degree atrioventric-
lar block or previous pacemaker. Only 40.4% of dual-
hamber ICD recipients fulfilled an indication for dual-
hamber pacing.
Complications associated with ICD implantation were
Abbreviations
and Acronyms
ICD  implantable
cardioverter-defibrillator
NCDR  National
Cardiovascular Data
Registry
SVT  supraventricular
tachycardiaore frequent with dual-chamber than with single-chamber hmodels (Table 3). After adjusting for patient demographic
characteristics, medical comorbidities, and diagnostic test
results listed in Table 1, dual-chamber ICD selection was
associated with 40% greater odds of a periprocedural com-
plication (Table 4).
In-hospital mortality was significantly higher in dual-
chamber ICD recipients (259 deaths [0.40%] with dual-
chamber devices vs. 91 deaths [0.23%] with single-chamber
devices). After adjusting for the same potential confounders,
dual-chamber ICD selection remained associated with 45%
greater odds of mortality compared with single-chamber
device selection (Table 4).
Discussion
In a large, multicenter population undergoing first-time ICD
implantation, dual-chamber defibrillators were implanted
nearly twice as often as single-chamber devices. Only 40% of
dual-chamber ICD recipients demonstrated an indication for
pacemaker therapy. Patients who received dual-chamber de-
vices experienced greater odds of procedure-related complica-
tions and in-hospital mortality compared with single-chamber
device recipients.
Appropriate ICD selection strategies remain controver-
sial. Recent guidelines do not specifically address single-
versus dual-chamber device selection, presumably because of
continued disagreement between published studies (11).
The use of dual-chamber ICDs in patients with a need for
dual-chamber pacing is widely accepted as appropriate. In
the NCDR population, fewer than one-half of patients
receiving dual-chamber ICDs demonstrated such a pacing
indication. Dual-chamber ICD selection for patients with
histories of supraventricular tachycardia (SVT) is more
contentious, as clinical trials in this area have yielded
divergent results. Detection enhancements using dual-
chamber technology have been shown to reduce inappro-
priate therapy due to SVT (5) and composite adverse clinical
end points (6), although other investigations have failed to
find an improvement in rhythm classification (7) or a
ifference in shocks with the use of dual-chamber algo-
ithms (8,9). Notably, the prevalence of atrial fibrillation
nd flutter was significantly higher in the dual-chamber
CD cohort, suggesting that a history of SVT may have
otivated atrial lead placement in a portion of these
atients.
Detrimental effects of dual-chamber pacing modes in
atients without an indication for pacemaker therapy have
dded to this debate. Among patients with heart failure
eceiving dual-chamber ICDs without a pacemaker indica-
ion, DDDR pacing was associated with an increased rate of
eath and heart failure hospitalization compared to a VVI
lgorithm (12). Advances in ICD programming, including
ual-chamber algorithms to preferentially allow native
trioventricular conduction, can reduce the burden of ven-
ricular pacing (13) and do not result in excess mortality or
eart failure exacerbations compared with VVI strategies
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improved clinical outcomes with dual-chamber ICD selec-
tion compared with an optimally programmed single-
chamber defibrillator in patients without a pacing indica-
tion. Our study did not consider device programming but
instead examined the upfront complications and mortality
associated with device implantation. Without algorithms
that can translate the additional information and therapies
afforded by an atrial lead into demonstrable benefit, the
frequent use of dual-chamber devices must be re-examined.
Concern for the development of a pacing indication after
initial ICD implantation has occurred may also influence
operators to choose dual-chamber devices. Goldberger et al.
(15), citing cost-based decision analysis, argued that all ICD
candidates should receive dual-chamber devices irrespective
Figure 1 Selection of Study Participants From the NCDR ICD R
All patients enrolled in the National Cardiovascular Data Registry (NCDR) Implanta
between January 1, 2006, and December 31, 2007, were included in the analysis
were excluded.of the need for a pacemaker or a history of SVT. Such a
strategy would obviate a device upgrade should a patient
subsequently develop an indication for dual-chamber ther-
apy. Importantly, this prior analysis assumed equal compli-
cation rates for single- and dual-chamber device implanta-
tion. Future discussions regarding appropriate defibrillator
selection must recognize the heightened incidence of ad-
verse events associated with dual-chamber ICDs, as proce-
dural complications come at a significant monetary cost,
prolong hospital length of stay, and may expose patients to
undue risk.
The higher complication and in-hospital mortality
rates among patients receiving dual-chamber devices in
our cohort persisted after controlling for potentially
confounding variables. We hypothesized that acute com-
ry
rdioverter-Defibrillator (ICD) Registry who underwent first-time ICD implantation
nts receiving biventricular devices and those with previous ICD implantationegist
ble Ca
. Patie
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NCDR Dual-Chamber ICD Complication Rates August 30, 2011:1007–13Baseline Characteristics of ICD RecipientsTable 1 Baseline Characteristics of ICD Recipients
Characteristic
ICD Type
p Value
Single Chamber
(n  39,560)
Dual Chamber
(n  64,489)
Admission characteristics
Age (yrs) 64.0 13.9 67.1 12.9 0.0001
Female 10,273 (26.0%) 16,255 (25.2%) 0.006
Race 0.0001
White 30,976 (78.3%) 52,991 (82.2%)
Black 6,371 (16.1%) 8,055 (12.5%)
Other 2,213 (5.6%) 3,443 (5.3%)
Insurer 0.0001
Medicare 23,140 (58.5%) 42,070 (65.2%)
Medicaid 2,591 (6.5%) 2,853 (4.4%)
Other government 475 (1.2%) 719 (1.1%)
Commercial 8,637 (21.8%) 12,336 (19.1%)
Health maintenance organization 3,116 (7.9%) 4,506 (7.0%)
Other 1,601 (4.0%) 2,005 (3.1%)
Hospitalized for ICD implantation 25,296 (63.9%) 35,951 (55.7%) 0.0001
History and risk factors
Syncope 6,970 (17.6%) 15,875 (24.6%) 0.0001
Family history of sudden death 1,923 (4.9%) 3,207 (5.0%) 0.42
Congestive heart failure 28,171 (71.2%) 43,228 (67.0%) 0.0001
NYHA functional class 0.0001
I 6,841 (17.3%) 12,034 (18.7%)
II 20,134 (50.9%) 30,009 (46.5%)
III 11,494 (29.1%) 20,470 (31.7%)
IV 1,091 (2.8%) 1,976 (3.1%)
Cardiac arrest 0.0001
No 35,207 (89.0%) 56,699 (87.9%)
Bradycardic 202 (0.5%) 798 (1.2%)
Tachycardic 4,151 (10.5%) 6,992 (10.8%)
Atrial fibrillation/atrial flutter 10,734 (27.1%) 18,419 (28.6%) 0.0001
History of VT 0.0001
None 26,335 (66.6%) 36,751 (57.0%)
Nonsustained VT 8,800 (22.2%) 17,437 (27.0%)
Monomorphic sustained VT 3,289 (8.3%) 8,061 (12.5%)
Polymorphic sustained VT 1,136 (2.9%) 2,240 (3.5%)
Abnormal sinus node function 6,399 (16.2%) 17,743 (27.5%) 0.0001
History of cardiac transplantation 95 (0.2%) 145 (0.2%) 0.62
Nonischemic dilated cardiomyopathy 12,197 (30.8%) 16,672 (25.9%) 0.0001
Ischemic heart disease 25,803 (65.2%) 44,358 (68.8%) 0.0001
Previous MI 0.0001
No 17,399 (44.0%) 27,238 (42.2%)
MI within 40 days of ICD implantation 2,601 (6.6%) 4,906 (7.6%)
MI 40 days before ICD implantation 18,291 (46.2%) 29,800 (46.2%)
MI within 40 days and 40 days 1,269 (3.2%) 2,545 (3.9%)
Previous CABG surgery 12,369 (31.3%) 22,795 (35.3%) 0.0001
Previous percutaneous coronary intervention 12,913 (32.6%) 22,597 (35.0%) 0.0001
Previous valvular surgery 2,152 (5.4%) 4,075 (6.3%) 0.0001
Previous pacemaker implantation 1,441 (3.6%) 5,290 (8.2%) 0.0001
Cerebrovascular disease 5,382 (13.6%) 9,458 (14.7%) 0.0001
Chronic lung disease 8,245 (20.8%) 13,943 (21.6%) 0.003
Diabetes 14,041 (35.5%) 22,751 (35.3%) 0.48
Hypertension 28,416 (71.8%) 48,353 (75.0%) 0.0001
Renal failure on dialysis 1,766 (4.5%) 2,616 (4.1%) 0.002
(Continued on next page)
; LPFB
ventric
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ients given that atrial lead implantation requires an
additional electrode fixation and, depending on tech-
nique, a potential second venipuncture. A recent study in
Canadian ICD recipients also demonstrated that peripro-
cedural adverse events directly correlated with the num-
ber of implanted leads (10). The results of our study
confirm and extend these findings in a large patient
population receiving care across a wide spectrum of
healthcare facilities in the United States. Because patients
were followed only until hospital discharge, it is ex-
tremely unlikely that pacing mode or other differences in
device programming could account for our findings.
Similarly, the disparate use of antiarrhythmic drugs
between cohorts would be unlikely to influence compli-
cations or mortality over this short time period. It is
possible that the dual-chamber device group included a
larger number of patients in whom left ventricular lead
placement was attempted and aborted, thereby enriching
the complication rate of this cohort. This is suggested by
the significantly higher rate of coronary venous dissection
(and pneumothorax) noted in the dual-chamber group.
However, repeat analyses performed after censoring pa-
tients who experienced coronary venous dissection did
ContinuedTable 1 Continued
Characteristic
Diagnostics
Ejection fraction (%)
PR interval (ms)
QRS duration (ms)
Atrioventricular conduction
Normal
First-degree heart block only
Any second- or third-degree heart block
Paced
Intraventricular conduction
Normal
LAFB or LPFB
RBBB
LBBB
RBBB  LAFB or RBBB  LPFB
Nonspecific
Paced
Creatinine (mg/dl)
BUN (mg/dl)
Sodium (mmol/l)
BNP (pg/ml)
Systolic blood pressure (mm Hg)
ICD indication
Primary prevention
Values are mean  SD or n (%).
BNP  brain natriuretic peptide; BUN  blood urea nitrogen; CABG
LAFB  left anterior fascicular block; LBBB  left bundle branch block
New York Heart Association; RBBB  right bundle branch block; VT not yield statistically different results, making it unlikelythat this misclassification accounts for the overall differ-
ences in complications and mortality between cohorts.
Although patients receiving biventricular ICDs are likely
to have more comorbidities than patients only eligible for
standard defibrillator therapy, multivariate analysis con-
trolling for baseline risk factors demonstrated increased
odds of complication and death with dual-chamber
device selection. Although absolute increases in compli-
cations and in-hospital mortality with the addition of an
atrial lead are small, this should be understood amid the
paucity of data supporting dual-chamber device superi-
ority in the absence of a pacing indication. We believe
that the excess mortality observed in dual-chamber ICD
ICD Type
p Value
le Chamber
 39,560)
Dual Chamber
(n  64,489)
.9 10.8 29.9 12.0 0.0001
.8 36.1 181.6 43.2 0.0001
.8 26.6 114.8 30.2 0.0001
0.0001
83 (85.4%) 46,065 (71.4%)
96 (10.9%) 12,243 (19.0%)
49 (1.4%) 2,811 (4.4%)
32 (2.4%) 3,370 (5.2%)
0.0001
57 (68.1%) 37,958 (58.9%)
12 (3.6%) 2,385 (3.7%)
85 (5.8%) 4,924 (7.6%)
32 (9.9%) 8,893 (13.8%)
27 (0.8%) 991 (1.5%)
01 (9.6%) 6,291 (9.8%)
46 (2.1%) 3,047 (4.7%)
.4 1.2 1.4 1.1 0.67
.7 13.1 23.0 13.1 0.0001
.6 3.5 138.5 3.5 0.017
.4 1,089.2 929.2 1,095.2 0.63
.3 21.9 131.3 22.6 0.0001
0.0001
13 (81.9%) 49,513 (76.8%)
nary artery bypass graft; ICD  implantable cardioverter-defibrillator;
 left posterior fascicular block; MI myocardial infarction; NYHA 
ular tachycardia.
Dual-Chamber ICD Recipients Withan Indic tion for Pacemaker TherapyTable 2 Dual-Chamber ICD Recipients Withan Indication for Pacemaker Therapy
Pacemaker Indication
Implantations Fulfilling
Criteria
Abnormal sinus node function 17,743 (27.5%)
Bradycardic cardiac arrest 7,790 (12.1%)
Previous pacemaker implantation 4,806 (7.5%)
Second- or third-degree atrioventricular block 2,811 (4.4%)
Any 1 of the above indications 26,052 (40.4%)Sing
(n
27
172
108
33,7
4,2
5
9
26,9
1,4
2,2
3,9
3
3,8
8
1
22
138
921
129
32,4
 coroValues are n (percent of total dual-chamber implants).
ICD  implantable cardioverter-defibrillator.
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procedure-related complications in this cohort, although
the observational nature of this study precludes a direct
assessment of causality. The nearly 60% of dual-chamber
device recipients in the NCDR ICD Registry who lacked
a guideline-based indication for pacemaker therapy paid
an infrequent but significant cost without promise of
clinical benefit.
Study limitations. The NCDR ICD Registry was devel-
oped to record ICD implantation data in a Medicare
primary prevention cohort. Data for patients meeting
secondary prevention criteria or with private insurance
were supplied electively. Although operators may have
censored certain secondary prevention or private insur-
ance payer implantations for unknowable reasons, it is
reassuring that 88% of defibrillator implantations re-
corded in the NCDR database were performed at hospi-
tals that registered data for all devices regardless of
Single- Versus Dual-ChamberICD Implantation Complication RatesTable 3 S ngle- Versus Dual-ChamberICD Implantation Complication Rates
ICD Type
Adverse Event Single Chamber Dual Chamber p Value
Cardiac arrest 91 (0.23%) 203 (0.31%) 0.01
Drug reaction 33 (0.08%) 69 (0.11%) 0.24
Cardiac perforation 22 (0.06%) 42 (0.07%) 0.55
Cardiac valve injury 0 (0.00%) 1 (0.01%) 0.43
Conduction block 7 (0.02%) 22 (0.03%) 0.12
Coronary venous dissection 4 (0.01%) 76 (0.12%) 0.001
Hematoma 282 (0.71%) 593 (0.92%) 0.001
Lead dislodgement 198 (0.50%) 565 (0.88%) 0.001
Hemothorax 22 (0.06%) 52 (0.08%) 0.14
Pneumothorax 144 (0.36%) 339 (0.53%) 0.001
Peripheral nerve injury 2 (0.01%) 3 (0.01%) 0.93
Peripheral embolus 7 (0.02%) 21 (0.03%) 0.16
Phlebitis (superficial) 10 (0.03%) 40 (0.06%) 0.009
Phlebitis (deep) 6 (0.02%) 17 (0.03%) 0.24
Transient ischemic attack 3 (0.01%) 13 (0.02%) 0.11
Stroke 21 (0.05%) 41 (0.06%) 0.50
Myocardial infarction 6 (0.02%) 23 (0.04%) 0.05
Pericardial tamponade 19 (0.05%) 59 (0.09%) 0.01
Arteriovenous fistula 0 (0.00%) 5 (0.01%) 0.08
Infection related to device 12 (0.03%) 18 (0.03%) 0.82
Any adverse event 833 (2.11%) 2,047 (3.17%) 0.001
All-cause mortality 91 (0.23%) 259 (0.40%) 0.001
Cardiovascular cause 56 (0.14%) 181 (0.28%) 0.001
Noncardiovascular cause 35 (0.09%) 78 (0.12%) 0.12
Death in laboratory 6 (0.02%) 17 (0.03%) 0.24
Values are n (%).
ICD  implantable cardioverter-defibrillator.
Odds of Adverse Events Associated With Dual-Chamber ICD ImplanTable 4 Odds of Adverse Events Associated With Dual-Chambe
Unadjusted OR 95% CI
Any complication 1.49 1.37–1.61
In-hospital mortality 1.69 1.42–2.01CI  confidence interval; ICD  implantable cardioverter-defibrillator; OR  odds ratio.insurance type or prevention indication (4). Although
device selection was associated with increased complica-
tions and mortality in multivariate models, residual
confounding due to unmeasured or imprecisely reported
variables could potentially account for our findings.
Finally, complication data were collected only through
the time of hospital discharge. It is possible that long-
term complication rates for these devices may diverge
from in-hospital rates.
Conclusions
Our study examined defibrillator implantation patterns in
a large, national cohort of patients receiving care at both
academic and community hospitals. Dual-chamber ICD
implantation is common, and nearly 60% of these devices
are used in patients without a pacing indication. Despite
their unclear clinical benefit, dual-chamber ICDs are
associated with increased odds of complications and
in-hospital mortality after implantation compared with
single-chamber devices. Given this heightened risk of
periprocedural complications, the routine use of dual-
chamber ICDs in patients without a pacing indication
should be questioned.
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